VYNE Therapeutics (VYNE)
(Real Time Quote from BATS)
$1.76 USD
-0.21 (-10.66%)
Updated Jun 28, 2024 10:22 AM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/12/24 |
---|---|
Current Quarter | -0.19 |
EPS Last Quarter | -0.15 |
Last EPS Surprise | 37.50% |
ABR | 1.00 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -0.77 |
Next Year | -0.79 |
EPS (TTM) | -5.28 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 0.11M | 0.11M | 0.40M | NA |
# of Estimates | 1 | 1 | 1 | NA |
High Estimate | 0.11M | 0.11M | 0.40M | NA |
Low Estimate | 0.11M | 0.11M | 0.40M | NA |
Year ago Sales | 0.14M | 0.11M | 0.42M | 0.40M |
Year over Year Growth Est. | -21.43% | 0.00% | -5.66% | NA |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.19 | -0.21 | -0.77 | -0.79 |
# of Estimates | 2 | 2 | 2 | 1 |
Most Recent Consensus | -0.19 | -0.21 | -0.77 | -0.79 |
High Estimate | -0.19 | -0.19 | -0.73 | -0.79 |
Low Estimate | -0.19 | -0.22 | -0.81 | -0.79 |
Year ago EPS | -3.08 | -1.85 | -2.72 | -0.77 |
Year over Year Growth Est. | 93.83% | 88.65% | 71.69% | -2.60% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 1 | 1 | 1 | 1 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 0 | 0 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.19 | -0.21 | -0.77 | -0.79 |
7 Days Ago | -0.19 | -0.21 | -0.77 | -0.79 |
30 Days Ago | -0.19 | -0.21 | -0.77 | -0.79 |
60 Days Ago | -0.25 | -0.25 | -1.00 | -0.96 |
90 Days Ago | -0.25 | -0.25 | -1.00 | -0.96 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.19 | -0.21 | -0.77 | -0.79 |
Zacks Consensus Estimate | -0.19 | -0.21 | -0.77 | -0.79 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.15 | -0.20 | -1.85 | -3.08 | NA |
Estimate | -0.24 | -0.50 | -0.76 | -1.99 | NA |
Difference | 0.09 | 0.30 | -1.09 | -1.09 | -0.45 |
Surprise | 37.50% | 60.00% | -143.42% | -54.77% | -25.17% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more